{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["AlphaMedix"]],"indication":null,"name":"NCT03466216","nct_id":"NCT03466216","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03466216. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"There is only a single treatment arm.","label":"AlphaMedix","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-04-06","type":"ACTUAL"},"conditions":["Neuroendocrine Tumor"],"enrollment":{"count":33,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AlphaMedix","otherNames":["Pb212-octreotide analog"],"type":"DRUG"}],"last_update":"2025-06-10","lead_sponsor":"Orano Med LLC","official_title":"A Phase 1, Non-Randomized, Open-Label, Dose Escalation, Single-Center Study to Determine the Safety, Bio-distribution, and Preliminary Effectiveness of AlphaMedix™ in Adult Subjects With SSRT(+) NETs.","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-04-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"To determine dose-limiting toxicity (DLT)","timeFrame":"8 weeks post-injection"},{"measure":"Incidence of treatment-emergent AEs and SAEs as assessed by CTCAE v. 4","timeFrame":"32 months after enrollment"}],"references":[],"start_date":{"date":"2018-02-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET","url":"https://clinicaltrials.gov/study/NCT03466216"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03466216"}